DOXY 200
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DOXY 200 (DOXY 200).
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex, and thus inhibiting peptide chain elongation. It is bacteriostatic and active against a broad range of gram-positive and gram-negative bacteria, as well as atypical organisms.
| Metabolism | Doxycycline is metabolized in the liver via oxidation and glucuronidation; it is not significantly metabolized by cytochrome P450 enzymes. |
| Excretion | Renal: 40% unchanged via glomerular filtration; Biliary/fecal: 20–25% as active drug and metabolites; remainder as inactive metabolites. |
| Half-life | Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 40 hours). |
| Protein binding | 80–93% bound primarily to albumin. |
| Volume of Distribution | Vd: 0.7–1.0 L/kg, indicating extensive tissue penetration. |
| Bioavailability | Oral: 90–100% (well absorbed); IV: 100%. |
| Onset of Action | Oral: 1–2 hours; IV: immediate (within minutes). |
| Duration of Action | 12–24 hours; sustained levels for up to 24 hours with standard dosing. |
200 mg orally once daily or 100 mg orally every 12 hours.
| Dosage form | INJECTABLE |
| Renal impairment | No adjustment necessary; doxycycline is not significantly renally excreted. |
| Liver impairment | No specific dosage adjustment recommended; use with caution in severe hepatic impairment. |
| Pediatric use | For children >8 years: 2.2 mg/kg/dose orally every 12 hours; maximum 200 mg/day. Not recommended for children <8 years due to risk of permanent tooth discoloration. |
| Geriatric use | No specific dose reduction; monitor for gastrointestinal intolerance and photosensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DOXY 200 (DOXY 200).
| Breastfeeding | Doxycycline is excreted into human breast milk. The milk-to-plasma ratio (M/P) is approximately 0.3–0.8. Theoretical risk of bone and tooth effects in nursing infants, but absorption is limited due to calcium binding in milk. The American Academy of Pediatrics considers doxycycline compatible with breastfeeding for short-term use. However, alternatives are preferred, especially for prolonged therapy. |
| Teratogenic Risk | Doxycycline (DOXY 200) is classified as FDA Pregnancy Category D. It crosses the placenta. First trimester: Associated with teratogenic effects including neural tube defects and cardiovascular anomalies, although data are conflicting. Second and third trimesters: Risk of permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus, as well as reversible inhibition of bone growth. Avoid use during pregnancy unless no alternative therapy is available. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to doxycycline or any tetracycline","Pregnancy (especially second and third trimesters)","Children under 8 years of age (except for treatment of anthrax or other life-threatening conditions)"]
| Precautions | ["Photosensitivity: Patients may experience exaggerated sunburn reaction; avoid prolonged sun exposure","Esophageal injury: Risk of esophageal ulceration if taken with insufficient fluid or lying down; administer with adequate fluids and remain upright","Use in pediatric patients <8 years: May cause permanent tooth discoloration and reversible bone growth inhibition","Use in pregnancy: Category D; may cause fetal harm if used during pregnancy","Superinfection: Prolonged use may result in overgrowth of non-susceptible organisms, including fungi","Central nervous system effects: May cause dizziness or lightheadedness; caution in driving or operating machinery"] |
| Food/Dietary | Avoid dairy products (milk, cheese, yogurt), calcium-fortified foods, and other calcium-rich meals within 2 hours of administration. Iron, zinc, magnesium, and bismuth subsalicylate also chelate and reduce absorption. Alcohol is not contraindicated but may increase risk of GI upset. Do not take with food containing high levels of polyvalent cations. |
Loading safety data…
| Fetal Monitoring | Maternal: Baseline and periodic liver function tests, renal function, and CBC due to potential hepatotoxicity and hematologic effects. Fetal: Ultrasound for skeletal development if used in second/third trimester. Monitor for signs of infant phototoxicity if continued near delivery. |
| Fertility Effects | Doxycycline may impair fertility in males by affecting sperm motility and morphology; effects are reversible upon discontinuation. No known significant effect on female fertility. In animal studies, high doses caused testicular atrophy. |
| Clinical Pearls | Administer with a full glass of water to reduce esophageal irritation. Avoid dairy products, antacids, and iron supplements within 2 hours of dosing due to chelation. Photosensitivity reactions are common; advise sun avoidance and sunscreen use. Monitor for superinfection, especially Clostridioides difficile diarrhea. May cause benign intracranial hypertension (pseudotumor cerebri) with headache and visual disturbances. |
| Patient Advice | Take exactly as prescribed; do not skip doses or stop early. · Swallow whole; do not crush or break tablet. · Take with plenty of fluids and avoid lying down for at least 30 minutes after taking. · Avoid dairy products, antacids, or iron supplements within 2 hours before or after taking this medicine. · Use effective birth control; may reduce oral contraceptive effectiveness. · Report severe headache, vision changes, or watery/bloody diarrhea immediately. · Avoid excessive sun exposure; use sunscreen and protective clothing. · Complete full course even if feeling better. |